case_images: PMC9685536_01
case_images: (A) Cranial enhanced MRI showing the right parietal lobe mass measuring approximately 2.1 cm (red arrow); (B) linear enhancement of leptomeninges in the left cerebral hemisphere (red box); (C) the right parietal lobe mass shrank 6 months after aumolertinib plus bevacizumab treatment; (D) linear enhancement of leptomeninges disappeared 6 months after aumolertinib plus bevacizumab treatment.
case_images: fonc-12-1040450-g001.jpg
case_images: PMC9685536_01_fonc-12-1040450-g001.jpg
case_images: f1
case_images: Figure 1 ). Furthermore, the effect of the combination therapy has lasted for >22 months and is still in close follow-up.
case_images: PMC9685536_02
case_images: (A) Cranial enhanced MRI showing linear enhancement of leptomeninges in the temporal lobe (red box); (B) linear enhancement of leptomeninges disappeared 2 months after aumolertinib plus bevacizumab treatment.
case_images: fonc-12-1040450-g002.jpg
case_images: PMC9685536_02_fonc-12-1040450-g002.jpg
case_images: f2
case_images: A repeated MRI revealed significant parenchymal and leptomeningeal lesion improvements ( Figure 2 ).
case_images: PMC9685536_03
case_images: (A) Cranial enhanced MRI showing left frontotemporal linear enhancement (red box); (B) linear enhancement of leptomeninges shrunk 2 months after aumolertinib plus bevacizumab treatment.
case_images: fonc-12-1040450-g003.jpg
case_images: PMC9685536_03_fonc-12-1040450-g003.jpg
case_images: f3
case_images: Figure 3 ). Furthermore, the efficacy has been durable for 10 months without any notable side effects.
case_images: PMC9685536_04
case_images: (A) Cranial enhanced MRI showing linear enhancement of ventricular ependyma (red arrow); (B) linear enhancement of leptomeninges regressed 2 months after aumolertinib plus bevacizumab treatment.
case_images: fonc-12-1040450-g004.jpg
case_images: PMC9685536_04_fonc-12-1040450-g004.jpg
case_images: f4
case_images: Leptomeningeal dissemination and brain metastases had regressed on MRI 2 months after the treatment initiation ( Figure 4 ).
case_images: PMC9685536_05
case_images: (A) Cranial enhanced MRI showing patchy high signals in the left temporal lobe (red box); (B) high signals of leptomeninges disappeared 2 months after aumolertinib plus bevacizumab treatment.
case_images: fonc-12-1040450-g005.jpg
case_images: PMC9685536_05_fonc-12-1040450-g005.jpg
case_images: f5
case_images: Leptomeningeal metastases showed a complete disappearance after 2 months of treatment ( Figure 5 ).